Equillium Q2 post narrower net loss than expected; starts R&D initiatives
EQ•Outlook and analyst coverage
-
Equillium expects to start Phase 1 EQ504 study in Q4 2026, with data about six months later
-
Company expects cash and cash equivalents to fund operations into 2029
-
Equillium is advancing IND-enabling activities for EQ504 as an inhaled therapy and EQ302 for celiac disease
-
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
-
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
-
Wall Street's median 12-month price target for Equillium Inc is $7.00, about 221.1% above its August 12 closing price of $2.18
Quarterly results beat expectations
- US biotech innovator's Q2 net loss narrowed and beat analyst expectations
- Q2 loss per share beat analyst expectations
- Company expects cash position to fund operations into 2029
| Metric | Beat/Miss | Actual |
